The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo

Zhu,Hong; Zhao,Fen; Yu,Shuijing; He,Jianping; Deng,Licong; Yi,Cheng; Huang,Ying

doi:10.3892/ijmm.2012.1105

The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo

Authors:
- Hong Zhu
- Fen Zhao
- Shuijing Yu
- Jianping He
- Licong Deng
- Cheng Yi
- Ying Huang
View Affiliations

Affiliations: Department of Abdominal Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathophysiology, West China School of Preclinical Sciences and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: August 21, 2012 https://doi.org/10.3892/ijmm.2012.1105
Pages: 1087-1094

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily that induces apoptosis in a broad range of human cancer cell lines while sparing most normal cell types. However, many tumors remain resistant to treatment with TRAIL. In this study, we investigated the synergistic effects of low-dose irinotecan (CPT-11) and TRAIL on TRAIL‑resistant HT-29 colon carcinoma cells and explored potential mechanisms of apoptosis. Cell viability was analyzed by sulforhodamine B (SRB) assay and apoptosis was evaluated by flow cytometry and DNA ladder assay. The mRNA expression of TRAIL receptors death receptor 4 (DR4) and DR5 were determined by reverse transcription polymerase chain reaction (RT-PCR). The changes of Bax and caspase-9 in protein levels were also detected by western blotting. Tumor growth curves were depicted and tumor inhibitive rates were calculated. Our results showed that the antitumor effect of TRAIL could be enhanced significantly by low-dose CPT-11 on TRAIL-resistant HT-29 cells both in vitro and in vivo. The synergistic apoptotic effect of CPT-11 and TRAIL was proposed to be mediated by upregulating DR5 mRNA expression and increasing expression of Bax and caspase-9 proteins. The data suggest that the combination of TRAIL with low-dose CPT-11 could be an effective therapeutic approach for HT-29 colon carcinoma.

View Figures

View References

1.	SJ OosterlingGJ van der BijM BogelsS ten RaaJA PostGA MeijerRH BeelenM van EgmondAnti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfacesAnn Surg2478594200810.1097/SLA.0b013e3181588583
2.	I HennebelleC TerretE ChatelutR BugatP CanalS GuichardCharacterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activityAnticancer Drugs11465470200010.1097/00001813-200007000-00007
3.	AM SaeternM BrandlWH BakkelundB SveinbjornssonCytotoxic effect of different camptothecin formulations on human colon carcinoma in vitroAnticancer Drugs15899906200410.1097/00001813-200410000-0001115457131
4.	AD SanliogluE DiriceO ElpekAF KorcumM OzdoganI SuleymanlarMK BalciTS GriffithS SanliogluHigh TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adeno-carcinoma patientsPancreas38154160200910.1097/MPA.0b013e31818db9e318981952
5.	A AshkenaziP HollandSG EckhardtLigand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)J Clin Oncol2636213630200810.1200/JCO.2007.15.7198
6.	J YooSS ParkYJ LeePretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cellsJ Cell Biochem10416361646200810.1002/jcb.2172918404675
7.	PG OliverAF LoBuglioKR ZinnH KimL NanT ZhouW WangDJ BuchsbaumTreatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11Clin Cancer Res1421802189200810.1158/1078-0432.CCR-07-139218381960
8.	R RaviAJ JainRD SchulickV PhamTS ProuserH AllenEG MayerH YuDM PardollA AshkenaziA BediElimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAILCancer Res6491059114200410.1158/0008-5472.CAN-04-248815604280
9.	K SugamuraJF GibbsA Belicha-VillanuevaC AndrewsEA RepaskyBL HylanderSynergism of CPT-11 and Apo2L/ TRAIL against two differentially sensitive human colon tumor xenograftsOncology74188197200810.1159/00015136618714167
10.	W ZhouJ HuH TangD WangX HuangC HeH ZhuSmall interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumorsBMC Cancer11485201110.1186/1471-2407-11-48522078414
11.	DD CuiY HuangSH MaoSC ChenM QiuLL JiC YiSynergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7Braz J Med Biol Res42854862200919738990
12.	YA YehM HerenyiovaG WeberQuercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cellsLife Sci5712851292199510.1016/0024-3205(95)02085-W7674820
13.	B LiuXC PengXL ZhengJ WangYW QinMiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivoLung Cancer66169175200910.1016/j.lungcan.2009.01.01019223090
14.	A TrunehS SharmaC SilvermanS KhandekarMP ReddyKC DeenMM McLaughlinSM SrinivasulaGP LiviLA MarshallTemperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptorJ Biol Chem2752331923325200010.1074/jbc.M91043819910770955
15.	FA KruytTRAIL and cancer therapyCancer Lett2631425200810.1016/j.canlet.2008.02.00318329793
16.	RW JohnstoneAJ FrewMJ SmythThe TRAIL apoptotic pathway in cancer onset, progression and therapyNat Rev Cancer8782798200810.1038/nrc246518813321
17.	R KoschnyH WalczakTM GantenThe promise of TRAIL-potential and risks of a novel anticancer therapyJ Mol Med85923935200710.1007/s00109-007-0194-117437073
18.	S LacourA HammannA WotawaL CorcosE SolaryMT Dimanche-BoitrelAnticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosisCancer Res61164516512001
19.	ES HensonJB JohnstonSB GibsonThe role of TRAIL death receptors in the treatment of hematological malignanciesLeuk Lymphoma492735200810.1080/1042819070171365518203008
20.	RK SrivastavaTRAIL/Apo-2L: mechanisms and clinical applications in cancerNeoplasia3535546200110.1038/sj.neo.790020311774036
21.	TR SinghS ShankarX ChenM AsimRK SrivastavaSynergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivoCancer Res63539054002003
22.	ER McDonald IIIPC ChuiPF MartelliDT DickerWS El-DeiryDeath domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signalingJ Biol Chem2761493914945200110.1074/jbc.M10039920011279061
23.	J WenN RamadeviD NguyenC PerkinsE WorthingtonK BhallaAntileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cellsBlood9639003906200011090076
24.	T NakaK SugamuraBL HylanderMB WidmerYM RustumEA RepaskyEffects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID miceCancer Res62580058062002
25.	M NaganeG PanJJ WeddleVM DixitWK CaveneeHJ HuangIncreased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivoCancer Res608478532000
26.	W LiuE BodleJY ChenM GaoGD RosenVC BroaddusTumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell linesAm J Respir Cell Mol Biol25111118200110.1165/ajrcmb.25.1.447211472983
27.	T MiyashitaJC ReedTumor suppressor p53 is a direct transcriptional activator of the human bax geneCell80293299199510.1016/0092-8674(95)90412-37834749
28.	N ShinouraS SakuraiA AsaiT KirinoH HamadaCaspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cellsNeurosurgery491771877200111440440
29.	MS SoengasRM AlarconH YoshidaAJ GiacciaR HakemTW MakSW LoweApaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibitionScience284156159199910.1126/science.284.5411.15610102818
30.	H LeBlancD LawrenceE VarfolomeevK TotpalJ MorlanP SchowS FongR SchwallD SinicropiA AshkenaziTumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog BaxNat Med8274281200210.1038/nm0302-27411875499
31.	G NunezMA BenedictY HuN InoharaCaspases: the proteases of the apoptotic pathwayOncogene1732373245199810.1038/sj.onc.12025819916986
32.	SH KaufmannWC EarnshawInduction of apoptosis by cancer chemotherapyExp Cell Res2564249200010.1006/excr.2000.483810739650
33.	R NimmanapalliCL PerkinsM OrlandoE O’BryanD NguyenKN BhallaPretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levelsCancer Res617597632001
34.	B GliniakT LeTumor necrosis factor-related apoptosis-inducing ligand’s antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11Cancer Res59615361581999